- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
PI3K Inhibitors and CAR T-Cell Therapy Find Their Niche in Indolent B-Cell Lymphomas
May 16, 2022
In relapse/refractory follicular lymphoma, promising results have been observed with PI3K inhibitors and are encouraging because of the less than optimal outcome associated with Bruton's tyrosine kinase inhibitors.
IS-002 is Well-Tolerated in Patients Undergoing Robotic Prostatectomy
May 16, 2022
IS-002 was shown to be safe, well-tolerated, and allow for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy, according to findings from a phase 1 study.
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study
May 16, 2022
Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Mitomycin Gel Maintains QOL in Patients With Low Grade Non-Muscle Invasive Bladder Cancer
May 16, 2022
Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Infigratinib Demonstrates Activity and Tolerability of FGFR Inhibition in Urothelial Carcinoma
May 16, 2022
Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC
May 16, 2022
Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Immunotherapy Offers Hopeful Outcomes in Nonmelanoma Skin Cancers
May 16, 2022
New and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.
Guidelines vs Pathways and Their Place in Oncology Practice
May 16, 2022
There is a role for these overlapping entities—guidelines and pathways—and each permits flexibility for the oncologist for available treatment options in the level and quality of data.
Neoadjuvant Axitinib May Enable Partial Nephrectomy in Subgroup of Patients with RCC
May 16, 2022
Neoadjuvant axitnib demonstrated significant reductions in tumor size and complexity, allowing for partial nephrectomy in a subgroup of patients with renal cell carcinoma.
Benefits and Risks of Stem Cell Transplant for Older Patients With MDS
May 16, 2022
Ronald L. Paquette, MD, discusses the choice of using bone marrow and stem cell transplants as treatment for patients with myelodysplastic syndrome.
Added Darolutamide Does Not Increase Toxicity With ADT/Docetaxel in mHSPC
May 16, 2022
Darolutamide plus androgen deprivation therapy and docetaxel was not associated with an increase in incidence or severity of adverse events versus androgen deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Benefit of Co-Treatment Chemotherapy and Vitamin C in Cisplatin-Ineligible MIBC
May 15, 2022
Chemotherapy plus intravenous vitamin C shows benefit in cisplatin-ineligible patients with locally advanced muscle-invasive bladder cancer.